Related Experiment Video
Updated: Jun 9, 2026
10:28
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Emerging antithrombotic agents: what does the intensivist need to know?
1Division of Cardiology, Newark Beth Israel Medical Center, Newark, NJ 07112, USA.
Current Opinion in Critical Care
|August 31, 2010
Summary
New anticoagulants and antiplatelet agents offer improved outcomes but carry bleeding risks. Careful patient selection and dosing are crucial for safe and effective antithrombotic therapy.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Background:
- Thrombus formation involves both fibrin and platelets, necessitating combined antithrombotic strategies.
- Traditional anticoagulants like unfractionated heparin have limitations, leading to the development of newer agents.
Purpose of the Study:
- To review recent advances in anticoagulant and antiplatelet therapies.
- To discuss the efficacy and safety profiles of novel antithrombotic agents.
Main Methods:
- Review of current literature on anticoagulants and antiplatelets.
- Comparison of efficacy and bleeding events of new agents versus established treatments.
Main Results:
- Newer parenteral anticoagulants (LMWH, fondaparinux, bivalrudin) are replacing unfractionated heparin.
- Oral direct thrombin inhibitors (dabigatran) show promise, outperforming vitamin K antagonists in atrial fibrillation.
- New antiplatelet agents (prasugrel, ticagrelor) are more effective than clopidogrel in ACS but increase bleeding risk.
Conclusions:
- Antithrombotic therapy has evolved with novel oral anticoagulants and potent antiplatelet agents.
- Bleeding risk is influenced by drug properties and clinical decision-making in patient management.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:30Venous Thrombosis IV: Nursing Management
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...